Hemophagocytic Lymphohistiocytosis
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Swedish Orphan BiovitrumMA - Waltham
2 programs1
EmapalumabPhase 2/3Monoclonal Antibody1 trial
Blood DrawsN/A1 trial
Active Trials
CT
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 program1
TQ05105Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Swedish Orphan BiovitrumEmapalumab
Chia Tai TianQing Pharmaceutical GroupTQ05105
Swedish Orphan BiovitrumBlood Draws
Clinical Trials (3)
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody
Start: Aug 2014Est. completion: May 2021
Phase 2/3Completed
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
Start: Jul 2020Est. completion: Jul 2022
Phase 1Unknown
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Start: Oct 2016Est. completion: Jan 2020
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space